A randomized, double-blind, placebo controlled bridging study of a new solid oral formulation of SYNB1618 in healthy volunteers
Latest Information Update: 30 Mar 2021
Price :
$35 *
At a glance
- Drugs SYNB-1618 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions
- Sponsors Synlogic
- 11 Dec 2021 According to a Synlogic media release, data will be presented at the American College of Medical Genetics (ACMG) meeting in April 2021.
- 13 Apr 2021 According to a Synlogic media release, data was presented at the American College of Medical Genetics (ACMG) meeting in April 2021.
- 13 Apr 2021 Results published in the Synlogic media release.